Treatment
Efgartigimod PH20 clinical trials
We’re tracking 12 recruiting studies that include Efgartigimod PH20, each written for real people, not researchers, below.
Recruiting studies
- NCT07782775RecruitingPhase 1
Comparing two ways to give efgartigimod in healthy volunteers
This study compares two methods of giving the drug efgartigimod under the skin in healthy adults. It helps ensure both methods work the same way, which may make treatment easier for patients in the future.
MontrealAges 18–55 - NCT05374590Enrolling by invitationPhase 2/Phase 3
Long-term safety study of efgartigimod for young myasthenia gravis patients
This trial checks the long-term safety of efgartigimod given through an IV and as a quick under-the-skin injection in children with generalized myasthenia gravis (gMG). It may help your care team understand how safely this treatment can be used over time for kids who already took related study treatments.
Chicago, IllinoisAges 2–18 - NCT06655155RecruitingPhase 2
Testing efgartigimod for systemic sclerosis
This trial tests an investigational drug called efgartigimod in people with systemic sclerosis (scleroderma). The goal is to see if it can safely reduce skin thickening and improve overall health. You might qualify if your skin is moderately affected and you have certain antibodies in your blood.
Phoenix, ArizonaAges 18 years+ - NCT07596849RecruitingPhase 3
Testing a New Injection for Graves' Disease
This study tests efgartigimod, a new medicine given by injection under the skin, to see if it can help control Graves' disease (an overactive thyroid condition). The goal is to reduce the need for other thyroid medications or help people stop taking them.
SurreyAges 18 years+ - NCT07570316RecruitingPhase 3
Testing efgartigimod for Graves' disease hyperthyroidism
This study tests whether efgartigimod, an injectable medication given under the skin, can help control overactive thyroid (Graves' disease) in adults already taking methimazole or carbimazole. The goal is to see if it reduces thyroid antibodies and improves thyroid hormone levels.
Orange, CaliforniaAges 18 years+ - NCT06909214RecruitingPhase 4
Study of efgartigimod for new-onset generalized myasthenia gravis
This study tests a new treatment called efgartigimod for people who have been recently diagnosed with generalized myasthenia gravis (gMG). It aims to see if this medicine can help manage symptoms like muscle weakness.
La Jolla, CaliforniaAges 18 years+ - NCT06392386RecruitingPhase 2/Phase 3
Efgartigimod for children with generalized myasthenia gravis
This study tests an investigational drug called efgartigimod for children and teens with generalized myasthenia gravis. It may help those who haven't responded well enough to standard treatments.
Charlotte, North CarolinaAges 2–17 - NCT07583641RecruitingPhase 2
Testing Efgartigimod for Autoimmune Brain Inflammation
This trial tests a medicine called efgartigimod to treat autoimmune encephalitis (AIE)—a rare condition where the immune system attacks the brain. The study enrolls children 12+ and adults to see if this drug can reduce symptoms and help recovery.
Tucson, ArizonaAges 12 years+ - NCT07294170Recruiting
Testing Multiple Treatments for Myasthenia Gravis
This trial tests multiple treatment combinations for people with myasthenia gravis (MG), a condition that causes muscle weakness. It aims to find safer and more effective options by comparing different therapies.
Carlsbad, CaliforniaAges 18 years+ - NCT07264426Recruiting
Real-world study of efgartigimod for CIDP
This study looks at how well efgartigimod works in everyday use for people with chronic inflammatory demyelinating polyneuropathy (CIDP). It aims to understand the real-world benefits of this treatment.
Wilmington, North CarolinaAges 18 years+ - NCT05979441Enrolling by invitationPhase 3
Long-term safety of efgartigimod injection for myositis
This study tests the long-term safety and effectiveness of a subcutaneous (under-the-skin) version of efgartigimod for adults with active idiopathic inflammatory myopathy. It is for people who have already completed an earlier study of this medicine.
Phoenix, ArizonaAges 18 years+ - NCT07673627RecruitingPhase 2
Testing empasiprubart for generalized myasthenia gravis
This trial tests a new drug called empasiprubart for people with generalized myasthenia gravis (gMG) who have a certain antibody (AChR-Ab). It is given as a monthly IV infusion (into a vein) and aims to improve muscle weakness and daily functioning.
Miami, FloridaAges 18 years+
What Efgartigimod PH20 is being studied for
Conditions with recruiting Efgartigimod PH20 studies.
Common questions
- Are there clinical trials studying Efgartigimod PH20?
- Yes. Clin2 currently lists 12 recruiting studies that include Efgartigimod PH20, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Efgartigimod PH20 trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Efgartigimod PH20 an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Efgartigimod PH20 or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.